Pharma Marketletter

View more issues:

Articles in August, 2004 issue of Pharma Marketletter

• Stock Commentary - Europe
• US HHS unveils strategy for Medicare Rx benefit and urges public comment
• Stock Commentary - New York
• At least 20% of US seniors are given inappropriate scripts, new study finds.
• Edwards' pledge on "misleading" drug ads.
• US Appeals Court to decide on US claims in Roche fraud case
• Global Rx drug prices up 8% in year to June 2004.
• AstraZeneca urges FDA on Crestor petition
• Indian drug price study sees large trade margins
• FDA OKs Seroquel labeling changes for BD
• Factive effective for CAP and ABECB
• Roche's MabThera cleared in EU for first-line use in non-Hodgkin's lymphoma
• BioMarin sees 2nd-qtr loss rocket on Ascent acquisition
• "Tremendous potential" of US embryonic stem cell policy: HHS Sec
• Stock Commentary - Europe.
• Global Rx drug prices up 8% in year to June 2004.
• Illinois to aid Rx-buying from Canada, UK, Ireland.
• Israel: complaints over funds' drug access
• Canadians overpaying for generics, says study.
• UK announces interim moves to boost pediatric drugs R&D, ahead of new EU reg.
• US Medicare-approved Rx discount cards evaluated
• Biotechnology firms are making a mark in Japan.
• NicOx' sales and loss are down for 1st half
• Tokyo pharma stocks - week to july 26.
• US Medicare Rx price cuts could close "doughnut" hole, but with costs to R&D: study.
• Pharma-Biotech alliances generating wave of new breast cancer therapeutics.
• Provisional results of Sanofi's offer for Aventis show adequate acceptance
• Scotland considers free statins plan.
• UPDATE: Australian PM accepts anti-evergreening demands, but warns they could kill AUSFTA
• 3% underlying sales rise at Yamanouchi.
• US FDA urges pharma over obesity drugs.
• Faster info on new drugs for UK NHS
• Tokyo pharma stocks - week to August 16.
• Time right for new drug delivery tech.
• UK announces interim moves to boost pediatric drugs R&D, ahead of new EU reg.
• USTR warns Australia over FTA Rx moves
• Canadian Premiers' national Rx plan too costly, says PM, backing catastrophic cover.
• US FDA responds to Vermont suit
• US FDA pediatric antidepressant use review update; public meeting Sept 13- 14
• US biotech sector tumbles in July as investors react to choppy market conditions.
• Vermont to sue US FDA over Canadian drugs.
• Australian Labour amendments to prevent "evergreening" delay AUSFTA Senate vote
• Euro nanotechnology consultation launched.
• Sankyo sales down but profits leap 60%
• 1st-qtr turnover rises 5.2% at Eisai
• Effects of French Rx de-reimbursement
• US group welcomes WHO ARV de-listing
• EU Commission "backs single euro Rx price"
• Stock Commentary - New York.
• Tokyo pharma stocks - week to August 9.
• Qiagen posts 2nd-qtr organic growth of 32%
• Canada: provinces urge national drug program
• George Bush has stood in the way of Canadian re-imports, says Kerry.
• Vermont files suit against FDA.
• Berna's share price slips as 1st-half losses rise
• Myriad Genetics posts record sales
• MediGene boosts R&D pipeline with Munich Biotech prods and technology.
• UPDATE: Teva to buy Pfizer's Italian generics unit in 69M-euro deal; sued by Aventis.
• George Bush has stood in the way of Canadian re-imports, says Kerry.
• Positive new results for Yamanouchi's solifenacin in the treatment of OAB
• Australia plans to fast-track PBS drugs
• Pharmacogenetics ethics and personal issues
• Tanabe sees net drop 37.7% in FY 1st qtr
• Vermont to sue US FDA over Canadian drugs
• Fortified milk prevents childhood diseases
• Poland aims to meet EU Rx regs to boost sales
• Israel: complaints over funds' drug access
• US biotech sector tumbles in July as investors react to choppy market conditions.
• US FDA near-term priorities: innovation, access, cGMPs, consumer protection
• Eisai/Pfizer's Aricept reduces behavior disturbances in AD patients; new study.
• US FDA urges pharma over obesity drugs.
• India: more essential drugs for price control.
• 3% underlying sales rise at Yamanouchi
• Chinese pharma hit by price cuts on antibiotics.
• Tokyo pharma stocks - week to August 16.
• "Excellent" results from Prexige study means Novartis will file for approvals.
• UK NICE "conquering the world, but...."
• AstraZeneca's Seroquel effective in treating agitation in elderly with dementia.
• Australia Rx review plan published for comment.
• New AD therapies designed to stop progression of disease not just symptoms.

• 1
• 2